Abbott Laboratories $ABT Holdings Reduced by Strengthening Families & Communities LLC

Strengthening Families & Communities LLC decreased its position in Abbott Laboratories (NYSE:ABT) by 46.3% in the 2nd quarter, Holdings Channel.com reports. The firm owned 277 shares of the healthcare product maker’s stock after selling 239 shares during the period. Strengthening Families & Communities LLC’s holdings in Abbott Laboratories were worth $37,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Hughes Financial Services LLC acquired a new stake in shares of Abbott Laboratories in the 1st quarter worth approximately $27,000. Abound Financial LLC acquired a new stake in shares of Abbott Laboratories in the 1st quarter worth approximately $28,000. Elequin Capital LP acquired a new stake in shares of Abbott Laboratories in the 1st quarter worth approximately $30,000. JCIC Asset Management Inc. acquired a new stake in shares of Abbott Laboratories in the 1st quarter worth approximately $32,000. Finally, Vision Financial Markets LLC acquired a new stake in shares of Abbott Laboratories in the 1st quarter worth approximately $33,000. Institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ABT. Morgan Stanley upped their price target on shares of Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Leerink Partnrs raised shares of Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. Evercore ISI increased their target price on shares of Abbott Laboratories from $140.00 to $144.00 and gave the company an “outperform” rating in a research note on Tuesday. BTIG Research cut their target price on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, July 18th. Finally, Benchmark initiated coverage on shares of Abbott Laboratories in a research note on Friday. They set a “buy” rating and a $145.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $146.17.

Abbott Laboratories Stock Down 0.8%

ABT stock opened at $132.30 on Friday. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company’s 50 day simple moving average is $132.54 and its 200-day simple moving average is $131.56. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The firm has a market capitalization of $230.26 billion, a P/E ratio of 16.58, a P/E/G ratio of 2.53 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio is currently 29.57%.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.